Industry News

• Pfizer and Keas partner to help consumers take a active role in health care  Pfizer and Keas announced they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients.
  Pfizer February 08, 2010  
• Abbott submits new automated ovarian cancer test for U.S. approval  A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the U.S. Abbott’s ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer.
  Abbott February 08, 2010  
• MDRNA reports positive results for Its proprietary siRNA delivery technology  MDRNA announced that its lead delivery system formulation demonstrated exceptional stability over a one year period under a variety of conditions. The DiLA2 formulation maintained in vivo knockdown activity with no observed loss in potency over the course of the year-long study.
  MDRNA, Inc. February 08, 2010  
• ALK-Abelló announces disease-modifying effect of GRAZAX® verified  ALK announces positive results from the second follow-up year in a long-term study (GT-08) with GRAZAX®, the company's grass allergy immunotherapy tablet. The results verify that the disease-modifying effect of GRAZAX® is sustained after completion of the recommended three-year treatment regimen.
  ALK-Abelló February 08, 2010  
• Racial dispartities persist in breast, colon cancer cases in U.S.  The incidence of advanced breast cancer diagnosis among black women remained 30 percent to 90 percent higher compared to white women between 1992 and 2004, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
  Fred Hutchinson Cancer Research Center February 08, 2010  
• MDRNA receives compliance extension from NASDAQ  MDRNA announced that it received a letter from NASDAQ Stock Market notifying the Company that it has a grace period of 180 days from its initial notice of non-compliance in which to regain compliance with the $50 million minimum Market Value of Listed Securities for continued listing on the NASDAQ.
  MDRNA, Inc. February 08, 2010  
• Tyson reports first quarter fiscal 2010 results  First quarter 2010 Net EPS was $0.42, a record for a first fiscal quarter, as compared to $(0.27) last year. All operating segments were profitable, with three above their normalized ranges.
  Tyson Foods, Inc. February 05, 2010  
• Tyson shareholders elect nine Board members  Shareholders of Tyson Foods elected nine people to the company's Board of Directors, including six independent directors. The vote was announced at Tyson's annual meeting of shareholders in Springdale, Arkansas.
  Tyson Foods, Inc. February 05, 2010  
• AVI BioPharma's drug candidate AVI-5038 receives European orphan drug designation  VI BioPharma announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy.
  AVI BioPharma, Inc. February 05, 2010  
• FDA issues guidance to help streamline medical device clinical trials   The FDA issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies. The Bayesian method makes it possible to combine data collected in previous studies with data from current trials.
  U.S. Food and Drug Administration February 05, 2010  

   (next 10 articles)